New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2012
10:32 EDTXOM, HTWR, AZN, COF, STD, ARMH, LGF, RY, BMCOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ARM Holdings (ARMH) upgraded to Neutral from Underweight at JPMorgan... AstraZeneca (AZN) upgraded to Equal Weight from Underweight at Barclays... BMC Software (BMC) upgraded to Positive from Neutral at Susquehanna... Banco Santander (STD) upgraded to Conviction Buy from Neutral at Goldman... Banco Santander upgraded to Overweight from Neutral at JPMorgan... HeartWare (HTWR) upgraded to Overweight from Equal Weight at Barclays... Royal Bank of Canada (RY) upgraded to Buy from Neutral at BofA/Merrill... Capital One (COF) upgraded to Overweight from Neutral at JPMorgan... Exxon Mobil (XOM) upgraded to Outperform from Market Perform at Raymond James... Lions Gate (LGF) upgraded to Above Average from Average at Caris.
News For ARMH;AZN;BMC;STD;HTWR;RY;COF;XOM;LGF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 23, 2015
16:06 EDTCOFCapital One reports Q2 EPS ex-items $1.78, consensus $1.97
Reports Q2 revenue $5.7B, consensus $5.74B.
15:04 EDTCOFNotable companies reporting after market close
Subscribe for More Information
12:12 EDTRYValeant beats RBC as biggest Canadian company by market value, Bloomberg says
Valeant (VRX) has surpassed Royal Bank of Canada (RY) as the largest Canadian company by market value on the Toronto Stock Exchange, Bloomberg reports. Valeant surged 4.5% to a total market value of C$111.3B at 11:21 AM in Toronto, beating the Royal Bank's C$108.3B market value, the report says. Reference Link
09:10 EDTHTWRNorthland sees HeartWare takeover as 'highly unlikely
Northland analyst Suraj Kalia believes the sympathy rally in shares of HeartWare (HTWR) after St. Jude Medical (STJ) announced the acquisition of Thoratec (THOR) could be short lived. HeartWare has already tried to sell itself to larger medical device companies over the past few years, Kalia tells investors in a research note, citing his own field work. He views a buyout of HeartWare at this stage as "highly unlikely" and feels speculation of a $102-$122 per share takeover price is based on "na´ve and unsophisticated" analysis. Kalia keeps an Underperform rating on HeartWare with a $60 price target. The maker of implantable heart pumps, following a two-day rally, closed yesterday at $88.21.
July 22, 2015
15:01 EDTCOFEarnings Watch: American Express reports after several 'top pick' mentions
American Express (AXP) is expected to report second quarter earnings after the close on July 22, with a conference call scheduled for 5:00 pm ET. American Express is a global financial services company specializing in credit card and pre-paid card products and services. EXPECTATIONS: Analysts are looking for earnings per share of $1.32 on revenue of $8.46B. The consensus range is $1.23-$1.41 for EPS and $8.29B-$9.01B for revenue, according to First Call. LAST QUARTER: On April 16, American Express reported first quarter EPS of $1.48 against expectations for $1.37, and revenue of $7.95B versus estimates of $8.21B. The company reported ROE of 29% and guided towards flat to modestly down FY15 EPS as it ramps investments to offset the March 2016 expiration of its Costco (COST) partnership. NEWS: On May 12, American Express authorized the repurchase of up to 150M company shares while also raising its dividend 12% to 29c per share. During the Bernstein Strategic Decisions Conference on May 28, company executives remarked that a "range" of co-brand deals would be coming up for American Express, adding that the loss of the Costco contract was not the "be-all, end-all" for the company. On June 17, Reuters reported that a U.S. appeals court affirmed a prior ruling that American Express can no longer block businesses from steering customers towards competitor cards, such as those of Visa (V) or Mastercard (MA). STREET RESEARCH: On April 27, Nomura downgraded American Express to Neutral from Buy, citing minimal upside to 2015 and 2016 estimates amid a lack of near-term catalysts. Meanwhile, Bernstein upgraded the stock to Outperform from Market Perform on May 6. On May 18, Deutsche Bank reiterated a Buy rating and $90 price target on American Express shares, saying it sees a $750M-$850M annual revenue opportunity through the "Plenti" loyalty program coalition. On June 2, Bernstein said it expects credit card volumes to grow 10%-12% annually over the next five years, adding that American Express, Capital One (COF) and Synchrony Financial (SYF) are its favorites in the sector. Following meetings with American Express executives, Citi called American's risk/reward ratio "attractive" on June 4, and on July 8, Deutsche Bank said it was positive on credit card stocks going into second quarter earnings, with American Express named a top pick. PRICE ACTION: Shares of American Express are near flat to $78.96 ahead of Wednesday's earnings report.
13:58 EDTAZNPiper cuts Array target by only 50c after failed trial
Piper Jaffray analyst Edward Tenthoff says selumetinib for Uveal Melanoma is a small indication and represented only a small part of his valuation for Array BioPharma (ARRY). As such, after partner AstraZeneca (AZN) announced that selumetinib failed in the Phase III trial, the analyst cut his price target for Array by only 50c to $14.50. The primary drivers for Array remain binimetinib and encorafenib in NRAS and BRAF melanoma and low-grade serous ovarian cancer, the analyst tells investors in a research note. He keeps an Overweight rating on the stock.
09:07 EDTAZNOn The Fly: Pre-market Movers
Subscribe for More Information
06:39 EDTXOMEuro, U.S. oil and gas groups to find tough competition in Iran, WSJ says
European and U.S. oil and gas firms drawn to Iran as sanctions lessen can expect not only opportunities, but also Iranian companies offering tough competition or joint ventures, the Wall Street Journal reports. Though no Iran-based companies have the clout of firms such as Exxon Mobil (XOM) or Schlumberger (SLB), companies that can take on engineering tasks are emerging and growing in Iran, the report says. If the Iran nuclear agreement comes into effect and sanctions are lifted against Iran sometime soon, those Iranian companies will be well positioned to compete for tens of billions of dollars worth of service contracts, the report adds. Other publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Royal Dutch Shell (RDS.A) and Total (TOT). Reference Link
06:13 EDTXOMExxon Mobil upgraded to Conviction Buy from Buy at Goldman
Subscribe for More Information
05:12 EDTAZNAstraZeneca says Phase 3 study of selumetinib did not meet primary endpoint
AstraZeneca (AZN) announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib. A full evaluation of the data is ongoing. Selumetinib is a MEK inhibitor in late-stage development, with a primary Phase 3 program in second-line KRAS-mutant advanced non-small cell lung cancer in combination with docetaxel. Selumetinib is also being investigated in a Phase 3 study in differentiated thyroid cancer and in a Phase 2 registration study in patients with neurofibromatosis Type 1. Selumetinib is an oral small molecule MEK inhibitor invented by Array BioPharma (ARRY) and licensed to AstraZeneca in 2003.
July 21, 2015
16:28 EDTHTWROn The Fly: Top stock stories for Tuesday
Subscribe for More Information
15:08 EDTHTWRThoratec reaches all-time high after report of St. Jude takeover
Subscribe for More Information
14:08 EDTARMHARM Holdings technical comments ahead of earnings
There is a potential bearish wedge on the daily chart that will either trigger following earnings news or fail depending on price direction. A move below $47.25 on bearish news would see the pattern become active. Downside potential for that pattern would be to the $41 to $40 area. If the news is instead a bullish surprise, any sustained move above $49.25 would void the pattern. Next resistance levels to watch as potential upside objectives would be at $50.66, $52.34, and $54.82. which is the 52-week high. The $55 area has been significant overhead resistance for the shares for the past two years. A move above that area would mark a new bullish leg up. If the outcome is bearish it should be noted that the $40 area when viewed on a long-term chart would mark the potential beginning of a double top.
12:40 EDTHTWRSt. Jude in talks to acquire Thoratec, Bloomberg reports
St. Jude Medical (STJ) is in talks to acquire Thoratec (THOR), Bloomberg reports, citing people familiar with the situation. Talks are ongoing and could still fall apart as no deal has been reached, Bloomberg adds. Thoratec shares spiked early in today's session, but a catalyst for the move was unclear before the Bloomberg report. Shares of the medical device maker focused on advanced heart failure patients are up $9.52 to $58.33 in midday trading. Its close competitor HeartWare (HTWR) is now up $5.53 to $84.70. Shares of St. Jude are up 4 to $76.61. Reference Link
12:33 EDTHTWRThoratec jumps after Bloomberg report of St. Jude buyout talks
Subscribe for More Information
10:20 EDTHTWRCatalyst behind Thoratec spike higher unclear
The catalyst behind the spike higher in shares of Thoratec (THOR) is unclear to traders and investors. The medical device maker focused on advanced heart failure patients rose as high $62.05 in early trading and its shares remain up 11%, or $5.48, to $54.29. Some vague takeover chatter surfaced, with St. Jude Medical (STJ) as the speculated buyer, but buyout rumors are often the "go-to" reason when stocks spike. Often the moves on rumors are less substantial than Thoratec's spike today. The company's close competitor HeartWare (HTWR) is not seeing any unusual trading thus far today, falling 36c to $78.81 in early trading.
10:14 EDTARMHHigh option volume stocks:
Subscribe for More Information
09:58 EDTHTWRThoratec jumps 14% to $55.82 in early trading
Subscribe for More Information
July 20, 2015
07:10 EDTHTWRHeartWare begins its MVAD System CE Mark international clinical trial
Subscribe for More Information
July 19, 2015
13:52 EDTARMHARM Holdings 'could climb' as Europe strengthens, Barron's says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use